New York State Common Retirement Fund Has $7.36 Million Position in Hologic, Inc. (NASDAQ:HOLX)

New York State Common Retirement Fund cut its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 6.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 119,122 shares of the medical equipment provider's stock after selling 7,827 shares during the period. New York State Common Retirement Fund owned 0.05% of Hologic worth $7,358,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in HOLX. Allworth Financial LP increased its holdings in shares of Hologic by 46.0% during the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock valued at $40,000 after purchasing an additional 216 shares during the period. Raiffeisen Bank International AG acquired a new position in shares of Hologic during the fourth quarter valued at $49,000. West Financial Advisors LLC acquired a new position in shares of Hologic during the first quarter valued at $50,000. Covestor Ltd increased its holdings in shares of Hologic by 49.3% during the fourth quarter. Covestor Ltd now owns 1,033 shares of the medical equipment provider's stock valued at $75,000 after purchasing an additional 341 shares during the period. Finally, Versant Capital Management Inc increased its holdings in shares of Hologic by 1,864.3% during the first quarter. Versant Capital Management Inc now owns 1,375 shares of the medical equipment provider's stock valued at $85,000 after purchasing an additional 1,305 shares during the period. 94.73% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Stephens lowered their price target on Hologic from $77.00 to $70.00 and set an "overweight" rating on the stock in a report on Tuesday, May 13th. Royal Bank Of Canada lowered their target price on Hologic from $75.00 to $70.00 and set a "sector perform" rating on the stock in a report on Friday, May 2nd. Citigroup raised Hologic from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $60.00 to $80.00 in a report on Wednesday, July 9th. Evercore ISI lifted their target price on Hologic from $62.00 to $68.00 and gave the stock an "in-line" rating in a report on Tuesday, July 8th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Hologic in a report on Tuesday, May 27th. Eleven analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $77.33.

Hologic Trading Up 0.9%

HOLX traded up $0.58 during trading on Wednesday, reaching $65.95. The company had a trading volume of 1,441,527 shares, compared to its average volume of 2,390,605. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $84.67. The company has a market cap of $14.70 billion, a price-to-earnings ratio of 27.83, a PEG ratio of 2.40 and a beta of 0.55. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.52 and a current ratio of 3.24. The firm's 50-day simple moving average is $62.72 and its 200 day simple moving average is $63.07.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.71% and a net margin of 13.83%. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. During the same period last year, the company posted $1.03 EPS. The business's quarterly revenue was down 1.2% compared to the same quarter last year. Equities research analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insider Activity

In other news, Director Martin D. Madaus purchased 5,445 shares of Hologic stock in a transaction dated Wednesday, May 7th. The stock was acquired at an average cost of $55.24 per share, for a total transaction of $300,781.80. Following the acquisition, the director directly owned 5,445 shares in the company, valued at $300,781.80. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 1.88% of the stock is currently owned by corporate insiders.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.